BioCentury | May 5, 2017
Company News

Pieris, AZ in respiratory deal for Anticalins

...respiratory disease candidates developed using the biotech's Anticalin platform. The deal includes preclinical asthma candidate PRS-060...
...of a Phase I trial of PRS-060, which the company plans to begin next half. PRS-060...
...Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Inflammation, Pulmonary Alex Himes PRS-060 AstraZeneca...
BioCentury | May 3, 2017
Company News

Pieris, AZ in respiratory deal for Anticalins

...front and another $12.5 million upon the start of a planned Phase I trial of PRS-060...
...product in the U.S. On a conference call Wednesday, President and CEO Stephen Yoder said PRS-060...
...With Wednesday's stock move, Pieris ended the day with a market cap of $158 million. Becky Simon PRS-060 AstraZeneca...
BioCentury | Jun 18, 2015
Distillery Therapeutics

Therapeutics: Interleukin-4 (IL-4; BSF1); IL-4 receptor (CD124; IL-4RA); interleukin-13 (IL-13)

...testing to treat asthma and dermatitis and Phase II for inflammation. Pieris Pharmaceuticals Inc. has PRS-060...
BioCentury | Dec 22, 2014
Company News

Pieris, Pieris Pharmaceuticals deal

...two preclinical compounds: anemia candidate PRS-080 , an Anticalin targeting hepcidin ; and asthma candidate PRS-060...
BioCentury | Jul 16, 2007
Clinical News

Pieris preclinical data

...In rats, pulmonary delivery of PRS-060 showed 10-fold higher bioavailability than historical data for pulmonary delivery...
...antibodies. Pieris is developing PRS-060, an anticalin, for asthma. Pieris AG , Freising, Germany Product: PRS-060...
Items per page:
1 - 5 of 5